Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

mit mittlerem Beobachtungszeitraum von 18 Monaten; Risikoverhältnis 0,96; obere Grenze des Konfidenzintervalls (KI) 1,16. Alogliptin ist ein Dipeptidylpeptidase-4-Inhibitor (DPP-4i) zur Behandlung von Diabetes Typ 2 bei Erwachsenen.

„Wir brauchen sicherere Diabetestherapien für Patienten mit einem erhöhten Risiko für kardiovaskuläre Erkrankungen", erklärte William B. White, MD, FASH, FAHA, FACP, leitender Forscher der EXAMINE-Studie. „Aufgrund der Auslegung der EXAMINE-Studie und der behandelten Hochrisiko-Patienten liefern diese Ergebnisse Klinikern, die Diabetespatienten mit Koronarerkrankungen behandeln, wertvolle Einblicke."

Die globale EXAMINE-Studie ist von Bedeutung, da sie die kardiovaskuläre Sicherheit bei Patienten mit erhöhtem Risiko für kardiovaskuläre Erkrankungen (KVE) ermittelt. KVE sind die Hauptursache für Morbidität und Mortalität bei Patienten mit Typ-2-Diabetes.

Es wurden insgesamt 5.380 Patienten zwischen 18 und 40 Monate nachbeobachtet. Die Anzahl an vorzeitigen Studienabbrüchen in beiden Gruppen war ähnlich. Die Patienten erhielten auch eine umfassende Standardtherapie für Diabetes Typ 2 und begleitende kardiovaskuläre Risikofaktoren.

„Das Design der EXAMINE-Studie und vor allem die gemessenen Ergebnisse machen diese Studie besonders interessant für die Diabetesbehandlung von Patienten mit hohem Risiko", sagte Ajay Ahuja, MD, Vice President, Global Medical Affairs, Takeda. „Im Laufe der vergangenen 20 Jahre hat Takeda eine solide Expertise für die Diabetesbehandlung aufgebaut und diese stets erweitert. EXAMINE zeigt unser anhaltendes Engagement für die Entwicklung neuer Produkte wie Alogliptin und für eine optimierte Behandlung des Diabetes Typ 2."

Der wichtigste sekundäre Endpunkt bestand aus den Komponenten des prim
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... YORK, May 24, 2011 Reportlinker.com ... report is available in its catalogue: ... (RVO) Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0511065/Retinal-Vein-Occlusion-RVO-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ...
... May 24, 2011 Reportlinker.com announces that ... in its catalogue: Triple ... http://www.reportlinker.com/p0284984/Triple-Analysis-Lung-Cancer-Lymphoma-and-Angiogenesis.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... drug development strategies in both Lung Cancer ...
Cached Medicine Technology:Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Nature, not nurture, may play ... chimpanzees, a new study finds. "As is the ... cognitive [thinking] abilities in chimpanzees," William Hopkins of the ... a news release from the journal Current Biology ... the evolution of intelligence in humans, Hopkins, team said. ...
(Date:7/10/2014)... who are sensitive to light or noise after a ... as anxiety and depression, a new study says. ... teens experience after concussion may help in planning for ... to return to play and what accommodations are needed ... and Dong Han, of the University of Kentucky in ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... Twitter wars that break out regularly between outspoken celebrities or ... your own relationship, a new study suggests. High amounts ... even if the couple is in a long-term relationship, according ... In turn, that friction can lead to cheating and ...
(Date:7/10/2014)... Emergency Medical Service (EMS) responders felt better prepared to ... tactical training according to a new study in the ... the first study to specifically examine the EMS provider ... a shooter has not yet been neutralized or working ... such as the Columbine High School shooting, the Virginia ...
Breaking Medicine News(10 mins):Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Active shooter training increases comfort level of emergency responders 2
... ... study finds that generic drugs to be equally as effective as brand name drugs. ... (PRWEB) November 19, 2009 -- ... the fear many people have about generic drugs. A systematic review of 47 studies comparing ...
... ... Month and to promote nutritional education, diet delivery company Bistro MD is holding a ... enter. , ... November 19, 2009 -- In celebration of National Novel Writing Month and to promote ...
... ... allows users to perform feature based reverse engineering functions with new added functionality ... ... 2009 -- Creative Dezign Concepts Inc today announced that DezignWorks, a feature ...
... , BEIJING, Nov. 19 ... ), a leading China-based,medical device company that develops, manufactures and ... the second fiscal quarter ended September 30, 2009 ("2Q FY2009"). ... ("FY2009"). , , 2Q FY2009 Highlights, ...
... 18 The American Association of Homes and Services for ... on ensuring that the Community Living and Supportive Services (CLASS) ... Long-term services and supports are an essential part of health ... of reform. We are also grateful to Sen. Dodd (D-Conn.) ...
... , CHICAGO, Nov. 18 Smoking cigarettes not only contributes ... pain and spine problems, according to recent studies and observations ... encouraging Americans to "kick the habit" during the Nov. 19 ... the American Cancer Society. Throughout this month, Dr. Karahalios will ...
Cached Medicine News:Health News:Generic Drugs Just as Effective as Brand Name Drugs Says DoctorSolve 2Health News:Diet Delivery Company Bistro MD Is Giving Away $1,500 in First Ever Creative Writing Contest 2Health News:Diet Delivery Company Bistro MD Is Giving Away $1,500 in First Ever Creative Writing Contest 3Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 2Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 3Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 4Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 5Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 2Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 3Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 4Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 5Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 6Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 7Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 8Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 9Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 10Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 11Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 12Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 13Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 14Health News:AAHSA Statement on Senate Health Reform Bill 2Health News:Smoking Contributes to Back Pain and Ineffective Surgical Treatments 2Health News:Smoking Contributes to Back Pain and Ineffective Surgical Treatments 3
... The ophthalmoscope with superior aspherical optics. ... illumination and observation beam by means of ... iris reflex (Gullstrand-principle). The Beta 200 allows ... illuminated section of the retina even with ...
Our standard ophthalmoscopes feature halogen light for true tissue color and consistent, long-lasting illumination, and six apertures for general and specialist use....
... an innovative and patented new optical ... enabling technology makes it easier to ... dramatically wider, more panoramic view of ... ever before achieved with a standard ...
The world's first automatic computation program analyzes massive amount of measurement data and computes "the most comfortable value" for the patient....
Medicine Products: